Biogen Inc. (NasdaqGS:BIIB) has been working with Goldman Sachs (GS) to find potential buyout targets and has a shopping list from the bank of potential acquisitions, STAT's Damian Garde and Adam Feuerstein reported, citing a person familiar with the matter. Goldman provided Biogen with a list of smaller biotech companies that might fit with the company's focus on neuroscience, including Biohaven Pharmaceutical (BHVN), Aurinia Pharmaceuticals (AUPH) and Amylyx (AMLX) and "the company's risk-averse board, which has repeatedly rejected potential deals, could be increasingly receptive," the biotech reporters said.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
228.8 USD | -1.27% |
|
+2.52% | -11.57% |
Jul. 02 | US Equities Markets End Higher Tuesday Following Fed Chair Powell's Comments | MT |
Jul. 02 | Equity Markets Mostly Rise Intraday After Fed Chair Powell's Comments | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.57% | 33.32B | |
+6.58% | 41.61B | |
+78.07% | 28.8B | |
-14.73% | 15.61B | |
-6.00% | 13.27B | |
-12.55% | 11.46B | |
+166.50% | 10.06B | |
-54.80% | 9.09B | |
+1.95% | 8.9B | |
-10.99% | 7.79B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen Reportedly Works with Goldman to Explore Possible Acquisitions